Agios Pharmaceuticals, Inc. AGIO
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- +12.18%
- 1 year
- -29.38%
- Open
- 30.95
- Prev close
- 30.55
- Mkt cap
- 1.82B
- Vol
- 720.26K
- Avg vol
- 1.08M
- EPS
- -7.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 30.43
- High
- 31.41
- Forward P/E
- -7.49
- Beta
- 0.63
- Short ratio
- 5.82
- Inst. own
- 115.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 33.69
- 200-d avg
- 31.69
- 1y target
- 45.88
5D chart
Signals (157)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:40 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 4 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 4 days ago |
| RSI: Oversold | Oct 29, 1:50 PM | 4 days ago |
| RSI: Oversold | Oct 29, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:35 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 10:05 AM | 6 days ago |
| RSI: Oversold | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 3:05 PM | 1 week ago |
| MACD: Buy Signal | Oct 26, 3:00 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:55 PM | 1 week ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 1 week ago |
| SMA: Bearish | Oct 26, 2:40 PM | 1 week ago |
| SMA: Bearish | Oct 26, 2:40 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:35 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:35 PM | 1 week ago |
| SMA: Bearish | Oct 26, 2:20 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:15 PM | 1 week ago |
| SMA: Bearish | Oct 26, 2:10 PM | 1 week ago |
| SMA: Bullish | Oct 26, 2:05 PM | 1 week ago |
| SMA: Bearish | Oct 26, 1:55 PM | 1 week ago |
| SMA: Bullish | Oct 26, 1:50 PM | 1 week ago |
| SMA: Bearish | Oct 26, 1:45 PM | 1 week ago |
| SMA: Bullish | Oct 26, 1:15 PM | 1 week ago |
| MACD: Buy Signal | Oct 26, 1:15 PM | 1 week ago |
| SMA: Bearish | Oct 26, 11:50 AM | 1 week ago |
| SMA: Bearish | Oct 26, 11:05 AM | 1 week ago |
| SMA: Bullish | Oct 26, 11:00 AM | 1 week ago |
| SMA: Bearish | Oct 26, 10:30 AM | 1 week ago |
News
3 days ago seekingalpha.com
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. Mitapivat's efficacy in SCD is mixed—endpoint for pain crises not…
-
3 days ago benzinga.com
Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major…
3 days ago globenewswire.com
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major…
4 days ago zacks.com
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
4 days ago benzinga.com
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
3 weeks ago globenewswire.com
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients…
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.
3 weeks ago zacks.com
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
1 month ago zacks.com
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
1 month ago benzinga.com
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
1 month ago defenseworld.net
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the…
2 months ago seekingalpha.com
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel
Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026…
2 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are…
2 months ago defenseworld.net
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the…
2 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are…
-
2 months ago benzinga.com
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
2 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are…
2 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are…
3 months ago defenseworld.net
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One…
-
3 months ago benzinga.com
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
3 months ago zacks.com
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $52 to $55.
3 months ago seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
3 months ago marketbeat.com
Agios Pharmaceuticals Q2 Earnings Call Highlights
Agios Pharmaceuticals NASDAQ: AGIO reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company…
3 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are…
3 months ago zacks.com
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.86. This compares to a loss of $1.93 per share a year ago.
-
3 months ago benzinga.com
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses…
3 months ago globenewswire.com
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial…
3 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 months ago benzinga.com
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $54 to $52.
3 months ago benzinga.com
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
-
3 months ago benzinga.com
Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in…
3 months ago benzinga.com
Why Is Agios Pharma Stock Soaring Tuesday?
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.
-
3 months ago benzinga.com
RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32
RBC Capital analyst Luca Issi maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Perform and raises the price target from $28 to $32.
3 months ago benzinga.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.
-
3 months ago benzinga.com
Agios Pharma Says FDA Accepts sNDA For Mitapivat In Sickle Cell Disease With Priority Review; PDUFA Goal Date November 1
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food…
-
3 months ago benzinga.com
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.
-
4 months ago benzinga.com
Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had…
-
4 months ago benzinga.com
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.
-
5 months ago benzinga.com
Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced an agreement with…
-
5 months ago benzinga.com
B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.
-
5 months ago benzinga.com
Agios Pharma Says It Will Not Advance Tebapivat, Next-Gen Oral Pyruvate Kinase Activator, In Lower-Risk Myelodysplastic Syndromes As Phase 2b Trial Results Did Not Meet Predefined Threshold To Support Further Development In LR-MDS
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observedCAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) --…
-
5 months ago benzinga.com
Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the European…
-
5 months ago benzinga.com
Agios Pharmaceuticals Submits Supplemental New Drug Application To FDA Seeking Accelerated Approval Of Oral Pyruvate Kinase Activator Mitapivat; To Also Present New Data On Mitapivat At 31st European Hematology Association Congress
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the submission of…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $36.